Mifeprex Labeling Change Not A Move Toward Product Withdrawal, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to strengthen warnings on the abortifacient was a “routine action” resulting from reports of serious adverse events, CDER Acting Director Galson says. “There was absolutely no political pressure on this,” he says, calling the labeling revision “science-based.”